Fig 1: IL-17A co-administration with DOX directly affects chemotherapeutic efficacy in cancer cells. (A) Ex vivo DOX sensitivity from 4T1-Thy1.1 cells isolated from primary tumors or from in vitro culture (n=12 from 3 independent tumors). (B) IC50 values extrapolated from dose response curves with error bars represent 95% CI. (C) Relative viability of 4T1-Thy1.1 cells cultured in the presence of DOX and/or IL-17A for 48 hours (n=9-11). ns: non-significant p > 0.05; *p = 0.05; ****p = 0.0001.